Charles River announces exclusive bioinformatics partnership with Fios Genomics
Charles River announced that it has entered into an exclusive partnership with Fios Genomics, a provider of bioinformatics data analysis services. Access to transparent bioinformatics presents a challenge for many drug development teams. Compiling complex data file types into single datasets for interpretation requires an assessment of data quality, as well as an analytical approach that emphasizes biological relevance and the assessment of statistical significance. Through this partnership, Charles River clients will have access to Fios Genomics' expertise in bioinformatics, statistics and biology to assist in the sourcing and analysis of the high-dimensional, multi-variant datasets associated with drug development including microarrays, next-generation sequencing, proteomics, metabolomics and epigenetics as well as the associated meta-data. The insights revealed by the team at Fios Genomics, combined with Charles River's integrated drug discovery and development platform and the scientific expertise of both organizations, will enable Charles River clients to make more data-driven decisions about their programs.